Study of mitapivat for sickle cell disease patients who need blood transfusions
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests whether a daily pill called mitapivat can reduce the number of blood transfusions you need. It is for people with sickle cell disease who have had at least one transfusion in the past year and are not on regular transfusion therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older.
- You have sickle cell disease (any type like SS, SC, or sickle beta thalassemia).
- You have had at least one blood transfusion in the past year but not more than 10 sickle cell pain crises.
- Your average hemoglobin level is between 5.5 and 10.5 g/dL and you have signs of red blood cell breakdown.
- You are not on regular blood transfusion therapy and haven't had a transfusion in the last 60 days.
- You are not currently taking other sickle cell disease treatments except hydroxyurea.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study provides continued access to the drug mitapivat for people who have already been in a mitapativ study and are benefiting from it.
This study tests an experimental pill called etavopivat for people with sickle cell disease who have had some pain crises in the past year. The goal is to see if it reduces these crisis episodes.
This trial studies etavopivat to see if it can improve blood-flow measurements in the brain that predict future stroke risk in children with sickle cell disease. If you qualify, you would take the study medicine and be monitored with brain blood-flow testing.
This Phase 1 study tests whether nicotinamide, oral tetrahydrouridine, and decitabine can help people with high-risk sickle cell disease. It is mainly a safety-and-dosing study, but it also looks for signs the medicines may improve disease-related problems.
This trial tests a new medicine called ITU512 in two groups: healthy volunteers and people with sickle cell disease. In the second part, researchers want to see if ITU512 can help manage sickle cell disease.
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.